Full-Life Technologies

Full-Life Technologies Limited is a fully integrated clinical-stage radiotherapeutics company developing next-generation radionuclide drug conjugates (RDCs) for precision cancer treatment. Founded in 2021, the company uniquely controls the entire value chain—from radiochemical research and drug discovery through Good Manufacturing Practices (GMP) production and clinical development—enabling it to address a critical market gap in the global supply and development of Actinium-225–based therapies. The company's lead program, 225Ac-FL-020, is an anti-prostate-specific membrane antigen (PSMA) radioligand therapy currently in Phase I clinical trials for metastatic castration-resistant prostate cancer (mCRPC) and has received FDA Fast Track designation. The company targets oncology centers, healthcare systems, and pharmaceutical partners seeking novel radiopharmaceutical solutions for difficult-to-treat solid tumors. Full-Life's revenue model centers on licensing agreements with pharmaceutical partners, manufacturing and supply contracts with healthcare providers, and potential future commercial sales following regulatory approval. Notably, the company has secured a $571.5 million licensing agreement with SK Biopharmaceuticals for worldwide development and commercialization rights to its FL-091 compound targeting neurotensin receptor 1 (NTSR1)–positive cancers. Keywords: radiopharmaceuticals, alpha emitter therapy, Actinium-225, precision oncology, radionuclide drug conjugates, PSMA, cancer therapeutics, clinical-stage biotech, deep tech, specialty pharma.